英国BIO-TRAC研究:生物制剂产品与批号可追溯性及电子不良反应报告的横断面研究
该研究通过英国医院药师在线调查和2009至2017年黄卡电子不良反应报告分析,评估生物制剂品牌名与批号的可追溯性。结果显示常规医院流程中品牌名记录率为79%至91%,批号记录率仅38%至58%;6108份电子报告中标明品牌名和批号者分别占38%和15%。结论认为英国不良反应报告中生物制剂可追溯性普遍较低。
要点
- 医院常规流程中生物制剂品牌名记录率79%至91%,批号记录率仅38%至58%。
- 黄卡电子报告中仅38%可识别品牌名,15%可识别批号。
- 2012年欧盟药物警戒立法后批号可追溯性略有改善,品牌名无改善。
核心结论
- 英国不良反应报告中生物制剂品牌名和批号的可追溯性普遍较低。
- 英国临床实践中产品细节系统性记录的不足可能导致可追溯性受限。
研究设计与样本
- 对英国医院药师进行在线调查,了解常规处方、调配和给药过程中生物制剂产品细节的记录方式。
- 分析2009年1月1日至2017年9月30日提交至英国黄卡计划的电子不良反应报告,评估标明品牌名和批号的比例。
主要发现
- 常规医院流程中品牌名记录率为79%至91%,批号记录率为38%至58%。
- 产品细节更常采用纸质记录方式。
- 共6108份针对重组生物制剂的电子不良反应报告提交至黄卡计划,其中38%可识别品牌名,15%可识别批号。
- 2012年欧盟药物警戒立法实施后,电子报告中批号可追溯性略有改善,但品牌名可追溯性未见改善。
临床怎么用
- 临床药师应推动在处方、调配和给药环节系统记录生物制剂的品牌名和批号。
- 上报生物制剂不良反应时,应尽量填写品牌名和批号以提高可追溯性。
局限性
- 研究基于医院药师调查和电子报告数据,可能未覆盖所有临床实践场景。
- 未报告调查样本量、报告填写完整性等具体细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Due to the complexity of biologics and the inherent challenges for manufacturing, it is important to know the specific brand name and batch number of suspected biologics in adverse drug reaction (ADR) reports. OBJECTIVE: The aim of this study was to assess the extent to which biologics are traceable by brand name and batch number in UK hospital practice and in ADRs reported by patients and healthcare professionals. METHODS: We performed an online hospital pharmacist survey to capture information on how specific product details are recorded during the processes of prescribing, dispensing and administration of biologics in routine UK hospital practice. We also assessed the proportion of ADR reports specifying brand name and batch number from electronic ADR reports submitted to the UK national spontaneous reporting database, the Yellow Card Scheme, between 1 January 2009 and 30 September 2017. RESULTS: Brand name recording in routine hospital processes ranged from 79 to 91%, whereas batch numbers were less routinely recorded, ranging from 38 to 58%. Paper-based recording of product details was more commonly used for recording information. A total of 6108 electronic ADR reports were submitted to the Yellow Card Scheme for recombinant biologics, of which 38% and 15%, respectively, had an identifiable brand name and batch numbers. Whereas batch number traceability in electronic ADR reports improved slightly after the implementation of the European Union pharmacovigilance legislation in 2012, no improvement of brand name traceability was observed. CONCLUSION: Brand name and batch number traceability for biologics in UK ADR reports are generally low. Shortcomings in the systematic recording of product details in UK clinical practice may contribute to the limited traceability.
引用
- Klein K, Hazell L, Stolk P, et al. The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UK. Drug Saf. 2020. PMID: 31872358. doi:10.1007/s40264-019-00891-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。